Imaging fibroblast activation in atherosclerosis using PET
PET Imaging of Fibroblast Activation in Carotid and Coronary Atherosclerotic Disease
This study is testing a special imaging technique to see if it can help doctors understand how active certain cells are in heart and neck artery blockages, which could help predict the risk of serious heart problems in patients.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 150 (estimated) |
| Ages | 18 Years to 90 Years |
| Sex | All |
| Sponsor | Peking Union Medical College Hospital Academic / other |
| Locations | 1 site (Beijing, Beijing) |
| Trial ID | NCT06280287 on ClinicalTrials.gov |
What this trial studies
This observational study evaluates the activation of fibroblasts in carotid and coronary atherosclerosis using positron emission tomography (PET) with a specific tracer, 68Ga-FAPI-04. It aims to correlate the in-vivo imaging results with histological markers of plaque vulnerability and clinical outcomes. The study focuses on patients with varying degrees of carotid stenosis and those with stable ischemic heart disease or acute coronary syndrome. By assessing fibroblast activation, the study seeks to enhance understanding of plaque stability and risk of rupture.
Who should consider this trial
Good fit: Ideal candidates include patients with symptomatic carotid stenosis greater than 50% or asymptomatic carotid stenosis greater than 70%, as well as those with stable ischemic heart disease or acute coronary syndrome.
Not a fit: Patients who are pregnant, lactating, or have contraindications to MRI or CTA will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved risk stratification and management of patients with atherosclerosis.
How similar studies have performed: While the use of PET imaging for fibroblast activation is a novel approach, similar imaging techniques have shown promise in assessing atherosclerotic plaque characteristics in other studies.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * For the carotid stenosis group: patients with symptomatic carotid stenosis with \>50% stenosis on carotid CTA; OR patients with unsymptomatic carotid stenosis with \>70% stenosis on carotid CTA * For CAD group: patients with stable ischemic heart disease OR acute coronary syndrome, including ST-elevation MId, non-ST elevation MI, and unstable angina * signed informed consent Exclusion Criteria: * Pregnancy, lactation, or intention to become pregnant during the study * Contradiction to MRI or CTA
Where this trial is running
Beijing, Beijing
- Peking Union Medical College Hospital — Beijing, Beijing, China (Recruiting)
Study contacts
- Study coordinator: Li Huo
- Email: huoli@pumch.cn
- Phone: +861069155513
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.